Corbus Pharmaceuticals Holdings, Inc.
CRBP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.7% and free cash flow fell 78.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CRBP
Corbus Pharmaceuticals Holdings, Inc. (CRBP) EV/Sales
As of 16 October 2026, Corbus Pharmaceuticals Holdings, Inc. (CRBP) trades at a EV/Sales of −5.2×. Over the past ten years it has ranged from −43.5× (March 2025) to 361× (August 2024); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | −1.7× | — |
| FY2020 | 7.8× | (13.95%) |
| FY2019 | 9.0× | (85.09%) |
| FY2018 | 60.4× | (56.16%) |
| FY2017 | 138× | (20.78%) |
| FY2016 | 174× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2021 | 26.1× | (44.04%) |
| Jun 2021 | 46.6× | 6.83% |
| Mar 2021 | 43.6× | 463.03% |
| Dec 2020 | 7.8× | (45.89%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. | −5.2× |
| RLYB Rallybio Corporation compare | −0.1× |
| KZIA Novogen Limited compare | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| EQ Equillium, Inc. compare | 2.0× |
| PMN Promis Neurosciences compare | 11,382× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)